Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) Stock Competitors & Peer Comparison
See CELG-RI's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CELG-RI and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CELG-RI | $0.12 | +5.05% | 254.5M | N/A | N/A | N/A |
| RPRX | $58.44 | +0.05% | 25.9B | 11.13 | $5.25 | +1.57% |
| CORT | $113.76 | +3.15% | 12.3B | 325.03 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $78.13 | +1.15% | 6B | 80.55 | $0.97 | N/A |
| LQDA | $66.43 | -0.67% | 5.9B | 48.49 | $1.37 | N/A |
| PBH | $46.80 | +4.07% | 2.2B | 10.59 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $21.11 | -6.39% | 1.3B | -11.41 | -$1.85 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
CELG-RI vs RPRX Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while RPRX trades at $58.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 11.13. In terms of profitability, CELG-RI's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CELG-RI is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CELG-RI vs CORT Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while CORT trades at $113.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 325.03. In terms of profitability, CELG-RI's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, CELG-RI is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
CELG-RI vs WBA Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, CELG-RI's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, CELG-RI is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
CELG-RI vs KNSA Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while KNSA trades at $78.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 80.55. In terms of profitability, CELG-RI's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CELG-RI is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
CELG-RI vs LQDA Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, LQDA has a market cap of 5.9B. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while LQDA trades at $66.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 48.49. In terms of profitability, CELG-RI's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CELG-RI is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
CELG-RI vs PBH Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, PBH has a market cap of 2.2B. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while PBH trades at $46.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas PBH's P/E ratio is 10.59. In terms of profitability, CELG-RI's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, CELG-RI is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
CELG-RI vs HROWL Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, CELG-RI's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CELG-RI is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
CELG-RI vs HROWM Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas HROWM's P/E ratio is N/A. In terms of profitability, CELG-RI's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CELG-RI is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
CELG-RI vs LTGO Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while LTGO trades at $21.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas LTGO's P/E ratio is -11.41. In terms of profitability, CELG-RI's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, CELG-RI is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check LTGO's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
CELG-RI vs HELP Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, HELP has a market cap of 846.7M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while HELP trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas HELP's P/E ratio is -3.28. In terms of profitability, CELG-RI's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, CELG-RI is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
CELG-RI vs SVA Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SVA's P/E ratio is -5.68. In terms of profitability, CELG-RI's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, CELG-RI is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check SVA's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
CELG-RI vs ETRA Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, ETRA has a market cap of 295.3M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while ETRA trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas ETRA's P/E ratio is -5.25. In terms of profitability, CELG-RI's ROE is N/A, compared to ETRA's ROE of N/A. Regarding short-term risk, CELG-RI is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check ETRA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
CELG-RI vs CUVL Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, CUVL has a market cap of 293.5M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while CUVL trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CUVL's P/E ratio is 12.56. In terms of profitability, CELG-RI's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, CELG-RI is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check CUVL's competition here
High Tide Inc. (NASDAQ: HITI)
CELG-RI vs HITI Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, HITI has a market cap of 231.1M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while HITI trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas HITI's P/E ratio is -9.71. In terms of profitability, CELG-RI's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, CELG-RI is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check HITI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
CELG-RI vs CTOR Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, CTOR has a market cap of 97.2M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while CTOR trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -2.22. In terms of profitability, CELG-RI's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CELG-RI is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
CELG-RI vs ATLN Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CELG-RI's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CELG-RI is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check ATLN's competition here
Stablecoin Development Corp. (AMEX: SDEV)
CELG-RI vs SDEV Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, SDEV has a market cap of 49.1M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while SDEV trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SDEV's P/E ratio is -0.17. In terms of profitability, CELG-RI's ROE is N/A, compared to SDEV's ROE of +7.90%. Regarding short-term risk, CELG-RI is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
CELG-RI vs RAD Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, CELG-RI's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, CELG-RI is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
CELG-RI vs GLTO Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CELG-RI's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CELG-RI is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
CELG-RI vs NSRX Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, NSRX has a market cap of 29.6M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while NSRX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -4.78. In terms of profitability, CELG-RI's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, CELG-RI is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
CELG-RI vs SCYX Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, SCYX has a market cap of 27.7M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while SCYX trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.29. In terms of profitability, CELG-RI's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CELG-RI is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CELG-RI vs COSM Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, COSM has a market cap of 18.4M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while COSM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.46. In terms of profitability, CELG-RI's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, CELG-RI is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check COSM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
CELG-RI vs BFRI Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, BFRI has a market cap of 14.9M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while BFRI trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -2.11. In terms of profitability, CELG-RI's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CELG-RI is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
CELG-RI vs CNSY Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, CNSY has a market cap of 13.1M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while CNSY trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CNSY's P/E ratio is -0.45. In terms of profitability, CELG-RI's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CELG-RI is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check CNSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
CELG-RI vs SCNX Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, SCNX has a market cap of 12.4M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while SCNX trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SCNX's P/E ratio is -0.15. In terms of profitability, CELG-RI's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, CELG-RI is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check SCNX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CELG-RI vs BFRIW Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, BFRIW has a market cap of 11.6M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, CELG-RI's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CELG-RI is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check BFRIW's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
CELG-RI vs CJJD Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CELG-RI's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CELG-RI is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
CELG-RI vs SSY Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, CELG-RI's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, CELG-RI is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
CELG-RI vs POM Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while POM trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.13. In terms of profitability, CELG-RI's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, CELG-RI is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
CELG-RI vs BGMS Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, BGMS has a market cap of 5.3M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while BGMS trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.27. In terms of profitability, CELG-RI's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CELG-RI is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check BGMS's competition here
Eocene Ltd. (NASDAQ: EOCN)
CELG-RI vs EOCN Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, EOCN has a market cap of 3.6M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while EOCN trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas EOCN's P/E ratio is -0.25. In terms of profitability, CELG-RI's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, CELG-RI is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
CELG-RI vs PAVS Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while PAVS trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.05. In terms of profitability, CELG-RI's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CELG-RI is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
CELG-RI vs MDVL Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CELG-RI's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CELG-RI is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
CELG-RI vs ATNFW Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CELG-RI's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CELG-RI is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
CELG-RI vs BGMSP Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CELG-RI's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CELG-RI is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
CELG-RI vs AZNH Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CELG-RI's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CELG-RI is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
CELG-RI vs LFLYW Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CELG-RI's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CELG-RI is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
CELG-RI vs PRPH Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, PRPH has a market cap of 148.9K. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas PRPH's P/E ratio is N/A. In terms of profitability, CELG-RI's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CELG-RI is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check PRPH's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
CELG-RI vs ESRX Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CELG-RI's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CELG-RI is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check ESRX's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
CELG-RI vs OREX Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, OREX has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, CELG-RI's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, CELG-RI is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
CELG-RI vs POZN Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, POZN has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, CELG-RI's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, CELG-RI is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check POZN's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
CELG-RI vs CPD Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, CPD has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas CPD's P/E ratio is N/A. In terms of profitability, CELG-RI's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, CELG-RI is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check CPD's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
CELG-RI vs IPXL Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CELG-RI's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CELG-RI is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CELG-RI.Check IPXL's competition here
Shire plc (NASDAQ: SHPG)
CELG-RI vs SHPG Comparison September 2026
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CELG-RI stands at 254.5M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CELG-RI is priced at $0.12 on the NYSE, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CELG-RI currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CELG-RI's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CELG-RI is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CELG-RI.Check SHPG's competition here